Aclidinium Bromide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Aclidinium Bromide |
| DrugBank ID | DB08897 |
| Brand Names (EU) | Bretaris Genuair |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 89.36% |
Approved Indication (EMA)
Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | open-angle glaucoma | 89.36% | DL |
| 2 | primary hereditary glaucoma | 88.95% | DL |
| 3 | migraine disorder | 86.15% | DL |
| 4 | migraine with brainstem aura | 85.36% | DL |
| 5 | irritable bowel syndrome | 84.56% | DL |
| 6 | headache disorder | 83.48% | DL |
| 7 | trigeminal autonomic cephalalgia | 82.74% | DL |
| 8 | glaucoma 1, open angle | 79.57% | DL |
| 9 | gastroduodenitis | 79.52% | DL |
| 10 | dermatitis | 79.28% | DL |
| 11 | obsolete rare pulmonary disease | 79.06% | DL |
| 12 | peptic ulcer disease | 78.54% | DL |
| 13 | dysthymic disorder | 78.03% | DL |
| 14 | acrodermatitis chronica atrophicans | 77.56% | DL |
| 15 | common cold | 77.20% | DL |
| 16 | neonatal dermatomyositis | 76.63% | DL |
| 17 | hydroa vacciniforme, familial | 75.98% | DL |
| 18 | atrophoderma vermiculata | 75.62% | DL |
| 19 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | 75.60% | DL |
| 20 | amyopathic dermatomyositis | 75.26% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.